Volume 10 - Spring Supplementary
Ann Appl Sport Sci 2022, 10 - Spring Supplementary: 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Musa S, Dergaa I, Tayebi S M. Emergence of SARS-CoV-2 B.1.1.7 and the Future of Mega Sport Events: Is This the Tipping Point from Pandemic to Endemic?. Ann Appl Sport Sci 2022; 10 (S1)
URL: http://aassjournal.com/article-1-1114-en.html
URL: http://aassjournal.com/article-1-1114-en.html
1- Primary Health Care Corporation (PHCC), Doha, P.O. Box 26555, Qatar
2- Primary Health Care Corporation (PHCC), Doha, P.O. Box 26555, Qatar ,idergaa@phcc.gov.qa
3- Department of Exercise Physiology, Faculty of Sport Science, Allameh Tabataba’i University, Tehran, Iran
2- Primary Health Care Corporation (PHCC), Doha, P.O. Box 26555, Qatar ,
3- Department of Exercise Physiology, Faculty of Sport Science, Allameh Tabataba’i University, Tehran, Iran
Abstract: (2114 Views)
No abstract as this is an Editorial
Type of Study: Editorial |
Subject:
Exercise, Training and Health
Received: 2022/02/2 | Accepted: 2022/03/17
Received: 2022/02/2 | Accepted: 2022/03/17
References
1. CDC COVID-19 Response Team. SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021. MMWR. 2021; 70(50):1731-34. [DOI:10.15585/mmwr.mm7050e1] [PMID] [PMCID]
2. Ingraham NE, Ingbar DH. The omicron variant of SARS-CoV-2: Understanding the known and living with unknowns. Clin Transl Med. 2021 Dec;11(12):e685. [DOI:10.1002/ctm2.685] [PMID] [PMCID]
3. Tian D, Sun Y, Zhou J, Ye Q. The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape. Front Immunol. 2021 Nov 30;12:751778. [DOI:10.3389/fimmu.2021.751778] [PMID] [PMCID]
4. Laurini E, Marson D, Aulic S, Fermeglia A, Pricl S. Computational mutagenesis at the SARS-CoV-2 spike protein/angiotensin-converting enzyme 2 binding interface: comparison with experimental evidence. ACS nano. 2021 March 18;15(4):6929-48. [DOI:10.1021/acsnano.0c10833] [PMID] [PMCID]
5. Chen J, Wang R, Gilby NB, Wei GW. Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. ArXiv [Preprint]. 2021 Dec 1:arXiv:2112.01318v1. [DOI:10.1021/acs.jcim.1c01451] [PMID] [PMCID]
6. Dyer O. Covid-19: Omicron is causing more infections but fewer hospital admissions than Delta, South African data show. BMJ. 2021 Dec 16;375:n3104. [DOI:10.1136/bmj.n3104] [PMID]
7. Zhao H, Lu L, Peng Z, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2022 Dec;11(1):277-283. [DOI:10.1080/22221751.2021.2023329] [PMID] [PMCID]
8. Wang L, Berger NA, Kaelber DC, et al. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv [Preprint]. 2022 Jan 2:2021.12.30.21268495. [DOI:10.1101/2021.12.30.21268495]
9. Davies MA, Kassanjee R, Rousseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. medRxiv. 2022 January 1. [DOI:10.1101/2022.01.12.22269148]
10. Lyngse FP, Mortensen LH, Denwood MJ, et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households. medRxiv. 2021 January 1. [DOI:10.1101/2021.12.27.21268278] [PMID] [PMCID]
11. Ferguson N, Ghani A, Cori A, et al. Report 49: Growth, population distribution and immune escape of Omicron in England. Imperial College London (16-12-2021),
12. Nasreen S, Chung H, He S, et al. Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat Microbiol. 2022 February 7. [DOI:10.1038/s41564-021-01053-0] [PMID]
13. Mladen Jergovic, Christopher P. Coplen, Jennifer L. Uhrlaub et al. Ellingson, Makiko Watanabe, Janko Nikolich-Žugich. Resilient T cell responses to B.1.1.529 (Omicron) SARS-CoV-2 variant
14. Ahmed SF, Quadeer AA, McKay MR. SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron. Viruses. 2022 January 2;14(1):79. [DOI:10.3390/v14010079] [PMID] [PMCID]
15. Pfizer. Pfizer and Biontech Provide an Update on Omicron Variant. (2021). Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant.
16. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf
17. Christensen PA, Olsen RJ, Long SW, et al. Early signals of significantly increased vaccine breakthrough decreased hospitalization rates, and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston, Texas. medRxiv. 2022 Jan 1:2021-12. [DOI:10.1101/2021.12.30.21268560]
18. Akbari HA, Pourabbas M, Yoosefi M, et al. How physical activity behavior affected well-being, anxiety and sleep quality during COVID-19 restrictions in Iran. Eur Rev Med Pharmacol Sci.2021.25(24), 7847-7857.
19. Dergaa I, Abubaker M, Souissi A, et al. Age and clinical signs as predictors of COVID-19 symptoms and cycle threshold value. Libyan Journal of Medicine. 2022:17(1), 2010337. [DOI:10.1080/19932820.2021.2010337] [PMID] [PMCID]
20. Varma A, Dergaa I, Mohammed AR, et al. Covid-19 and diabetes in primary care-How do hematological parameters present in this cohort?. Expert review of endocrinology & metabolism.2021:16(3), 147-153. [DOI:10.1080/17446651.2021.1909472] [PMID]
21. Dergaa I, Abdelrahman H, Varma A, et al. COVID-19 vaccination, herd immunity and the transition toward normalcy: challenges with the upcoming sports events. Annals of Applied Sport Science. 2021:9(3), 0-0. [DOI:10.52547/aassjournal.1032]
22. Dergaa I, Varma A, Tabben M, et al. Organising football matches with spectators during the COVID-19 pandemic: What can we learn from the Amir Cup Football Final of Qatar 2020? A call for action. Biology of Sport, 38(4), 677. [DOI:10.5114/biolsport.2021.103568] [PMID] [PMCID]
23. Dergaa I, Saad HB, Souissi A et al. Olympic Games in COVID-19 times: lessons learned with special focus on the upcoming FIFA World Cup Qatar 2022. British Journal of Sports Medicine. [DOI:10.1136/bjsports-2021-105276] [PMID]
24. Dergaa I, Musa S, Romdhani M, et al. FIFA World Cup 2022: What can we learn from the inspiring Tokyo 2020 Olympic Games held in COVID-19 times?. Biology of Sport. 2022:39(4), 1073-1080. [DOI:10.5114/biolsport.2022.113293]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
